- Start date
- 08 Dec 2024
- End date
- 08 Dec 2024
- Location
- Hall 407
Programme
12:30
Introduction and background of locally advanced and metastatic urothelial cancer
Ignacio Duran, Santander, Spain
12:35
Optimal definition of patient populations: Platinum eligibility and biology-informed science
Thomas B. Powles, London, United Kingdom
12:50
ESMO Guidelines on state-of-the art management of patients with first-line locally advanced and metastatic urothelial cancer and applicability in Asia Pacific
Xinan Sheng, Beijing, China
13:05
Continuum of care after progression on first-line therapy: Testing and rationalising
Ignacio Duran, Santander, Spain
13:20
Optimal management of ADC toxicities in patients with urothelial malignancies
Andrew J. Weickhardt, Melbourne, VIC, Australia
13:30
Case presentation of a patient with metastatic urothelial cancer: Criteria for choosing the right regimens in first-line and second-line locally advanced and metastatic urothelial cancer
Eun Hee Jung, Seoul, Republic of Korea
13:40
Panel discussion
All speakers
13:55
Summary and conclusion
Thomas B. Powles, London, United Kingdom
Learning objectives
- To be updated on state-of-the-art management of patients with advanced urothelial cancer
- To be provided insights on optimal patient selection informed by clinical and biological parameters
- To obtain expert insights on rationalizing the continuum of care for patients with advanced urothelial cancer
